A Phase 2 Single Arm Study of Elotuzumab in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Multiple Myeloma Relapsed or Refractory to Prior Treatment with Lenalidomide
ID Number 16-0648Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to determine the safety and effectiveness (how well the drug works) of the experimental new drug elotuzumab in combination with pomalidomide and low dose dexamethasone for the treatment of multiple myeloma patients who have relapsed after or are refractory to a prior treatment with a lenalidomide-based regimen.
Recruiting Patients: Yes